Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis

Abstract

The aim of the study is to characterize the expression pattern of galectin-3 (Gal-3) in renal tissues of patients with systemic lupus erythematosus (SLE) nephritis and to determine whether tissue and serum Gal-3 are associated with SLE nephritis. Gal-3 expressions were examined with immunohistochemistry in renal biopsy specimens of 88 patients with SLE nephritis and in five normal specimens. Activity and chronicity indexes and glomerular Gal-3 expressions were analysed in each specimen. Serum Gal-3 levels were measured using enzyme-linked immunosorbent assays in 20 patients with SLE, including 11 with nephritis, and in 50 healthy controls. Glomerular Gal-3 expression was observed in 81.8% (72/88) of patients with SLE nephritis but not in 5 controls. Gal-3 staining was attributed mainly to its cellular expression rather than its deposition, and Gal-3 expression levels were correlated with histologic activity indexes, anti-dsDNA titers, and complement 3 and 4 levels. Serum Gal-3 levels were higher in patients with SLE, particularly in those with nephritis, than in healthy controls, and correlated with anti-dsDNA titers. In conclusion, glomerular Gal-3 expression in renal tissue and serum Gal-3 levels were elevated in patients with SLE nephritis versus healthy controls; moreover, they reflected disease activity. These findings suggest that Gal-3 might contribute to the inflammatory process in SLE.

Keywords

galectin-3 lupus nephritis systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 Barondes SH Cooper DN Gitt MA Leffler H . Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807–20810.

2 Dumic J Dabelic S Flogel M . Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616–635.

3 Hsu DK Zuberi RI Liu FT . Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem 1992; 267: 14167–14174.

4 Menon RP Hughes RC . Determinants in the N-terminal domains of galectin-3 for secretion by a novel pathway circumventing the endoplasmic reticulum-Golgi complex. Eur J Biochem 1999; 264: 569–576.

5 Barboni EA Bawumia S Henrick K Hughes RC . Molecular modeling and mutagenesis studies of the N-terminal domains of galectin-3: evidence for participation with the C-terminal carbohydrate recognition domain in oligosaccharide binding. Glycobiology 2000; 10: 1201–1208.

6 van den Brule F Califice S Castronovo V . Expression of galectins in cancer: a critical review. Glycoconj J 2004; 19: 537–542.

7 Dagher SF Wang JL Patterson RJ . Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci U S A 1995; 92: 1213–1217.

8 Yang RY Hsu DK Liu FT . Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996; 93: 6737–6742.

9 Fukumori T Takenaka Y Oka N . Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res 2004; 64: 3376–3379.

10.

10 Liu L Sakai T Sano N Fukui K . Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem J 2004; 380: 31–41.

11.

11 Inohara H Raz A . Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995; 55: 3267–3271.

12.

12 Swarte VV Mebius RE Joziasse DH Van den Eijnden DH Kraal G . Lymphocyte triggering via L-selectin leads to enhanced galectin-3-mediated binding to dendritic cells. Eur J Immunol 1998; 28: 2864–2871.

13.

13 Ochieng J Leite-Browning ML Warfield P . Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun 1998; 246: 788–791.

14.

14 Jeng KC Frigeri LG Liu FT . An endogenous lectin, galectin-3 (epsilon BP/Mac-2), potentiates IL-1 production by human monocytes. Immunol Lett 1994; 42: 113–116.

15.

15 Sano H Hsu DK Yu L . Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165: 2156–2164.

16.

16 Nieminen J St-Pierre C Sato S . Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J Leukoc Biol 2005; 78: 1127–1135.

17.

17 Frigeri LG Zuberi RI Liu FT . Epsilon, BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells. Biochemistry 1993; 32: 7644–7649.

18.

18 Dong S Hughes RC . Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells. FEBS Lett 1996; 395: 165–169.

19.

19 Ohshima S Kuchen S Seemayer CA . Galectin-3 and its binding protein in rheumatoid arthritis. Arthritis Rheum 2003; 48: 788–795.

20.

20 Lee YJ Kang SW Song JK . Serum galectin-3 and galectin-3 binding protein levels in Behçet’s disease and their association with disease activity. Clin Exp Rheumatol 2007; 25(Suppl. 45): S41–S45.

21.

21 Lim Y Lee DY Lee S . Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun 2002; 295: 119–124.

22.

22 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

23.

23 Churg J Sobin LH . Renal Disease: Classification and Atlas of Glomerular Disease. Igaku-Shoin: Tokyo; 1982.

24.

24 Austin HA Muenz LR Joyce KM Antonovych TT Balow JE . Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–695.

25.

25 Kikuchi Y Kobayashi S Hemmi N . Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol Dial Transplant 2004; 19: 602–607.

26.

26 Hsu DK Yang RY Pan Z . Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 2000; 156: 1073–1083.

27.

27 Sano H Hsu DK Apgar JR . Critical role of galectin-3 in phagocytosis by macrophages. J Clin Invest 2003; 112: 389–397.

28.

28 Sasaki S Bao Q Hughes RC . Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 1999; 187: 481–489.

29.

29 Kasper M Hughes RC . Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 1996; 179: 309–316.

30.

30 Lippert E Falk W Bataille F . Soluble galectin-3 is a strong, colonic epithelial-cell-derived, lamina propria fibroblast-stimulating factor. Gut 2007; 56: 43–51.

31.

31 Henderson NC Mackinnon AC Farnworth SL . Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006; 103: 5060–5065.

32.

32 Goumenos D Tsomi K Iatrou C . Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol Dial Transplant 1998; 13: 1652–1661.

33.

33 Boukhalfa G Desmouliere A Rondeau E Gabbiani G Sraer JD . Relationship between alpha-smooth muscle actin expression and fibrotic changes in human kidney. Exp Nephrol 1996; 4: 241–247.

34.

34 Goumenos DS Tsamandas AC Oldroyd S . Transforming growth factor-beta(1) and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001; 87: 240–248.

35.

35 Holzman LB Wiggins RC . Consequences of glomerular injury. Glomerular crescent formation. Semin Nephrol 1991; 11: 346–353.